Oncoteq

Curated by Signal

Provider of AI-based technology for developing cancer therapeutics

Overview

Provider of AI-based technology for developing cancer therapeutics. It offers a pipeline of drug candidates which include TEQ101 for MetAP2 inhibition to treat Renal cell carcinoma, TEQ102 to target CD30 lymphomas, and TEQ103 for breast cancer.

Key facts

Founded: 2022
Headquarters: Cham, Switzerland
Stage: Sign up to view
Industry: Life Sciences Technology

Contact

Email: Sign up to view
Phone: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Helixstreet
Ethereum-based DNA analytics solution
Life Sciences TechnologyBasel, Switzerland
Nebion
Provider of software and services for biomarker and target discovery
Life Sciences TechnologyZurich, Switzerland
Daysy
Smart fertility tracking thermometer
Life Sciences TechnologyZurich, Switzerland

About Oncoteq

What does Oncoteq do?

Provider of AI-based technology for developing cancer therapeutics.

Where is Oncoteq headquartered?

Oncoteq is headquartered in Cham, Switzerland.

When was Oncoteq founded?

Oncoteq was founded in 2022.

Which sector is Oncoteq in?

Oncoteq operates in Life Sciences Technology.

Who are Oncoteq's competitors?

Companies similar to Oncoteq include Helixstreet, Nebion, and Daysy.